Stockreport

Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
PDF PURPOSE 1 is a phase III, double-blind, randomized study evaluating the safety and efficacy of twice-yearly, subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP [Read more]